Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)

Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06168955

Acronym

HO-MA

Enrollment

Registered

2023-12-13

Start date

2024-02-29

Completion date

2025-12-31

Last updated

2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

Alzheimer Disease, Genetic, N-homocysteinylation

Brief summary

Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction. This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.

Interventions

OTHERskin biopsy

skin biopsy for cell culture and N-homocysteinylation study

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* age \> 18 years * Age of onset of AD \< 75 years * Person with AD with positive CSF biomarkers * Person who has previously benefited from an analysis of AD genetic characteristics (APP, PSEN1, PSEN2, TREM2, ABCA7, SORL1 genes and ApoE status) and an analysis of monocarbon metabolism genes in the case of biochemical abnormalities by clinical exome, targeted panel or complete exome, and for whom the data set is already available.

Exclusion criteria

* Pregnant, parturient or breast-feeding women * Minor (not emancipated) * Person of legal age (subject to a legal protection measure) * Adult unable to give consent

Design outcomes

Primary

Measure	Time frame
MAP1 homocysteinylation level	Baseline

Secondary

Measure	Time frame
Homocysteinylation level of tau protein	baseline

Countries

France

Contacts

Primary ContactMathilde Renaud

cppest1@chlcdijon.fr0380425485

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026